Health & Healthcare

KFSHRC Reinforces Global Leadership as Early Adopter of Advanced cell and Gene Therapies

KFSHRC Reinforces Global Leadership as Early Adopter of Advanced cell and Gene Therapies

KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.
KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.

SAUDI ARABIA, Riyadh, Sept. 03, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has reaffirmed its global standing as a pioneer in advanced medical technologies by successfully establishing in-house manufacturing and clinical application of CAR-T therapy, placing itself among the select global centers driving the future of precision medicine.

KFSHRC has administered the first dose of locally manufactured Lentigen CD19 CAR-T therapy to a patient enrolled in a Phase I clinical trial for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), marking a breakthrough moment for the Kingdom in advanced gene and cell therapies.

Since 2020, KFSHRC has treated more than 200 patients with CAR-T therapies manufactured abroad, before advancing to become the first institution in the Kingdom to both manufacture and administer an in-house CAR-T product under a Phase I clinical trial. Unlike conventional CAR-T, which requires overseas production, the hospital’s in-house platform has reduced costs to just 20% of commercial CAR-T, eliminated logistical delays, and accelerated access to potentially life-saving treatment.

This milestone reflects integrated collaboration between KFSHRC’s department of Hematology, stem of transplantation and  therapy, Research & Innovation (R&I), Department of Pathology & Laboratory Medicine (DPLM), Center for Genomic Medicine (CGM), and Clinical Research Department (CRD) combining research, manufacturing, and clinical care under one roof to reshape healthcare access and outcomes.

KFSHRC will showcase its pioneering role in cell and gene therapies as strategic partner of the C3 Davos of Healthcare™ New York Summit: Healthcare Disrupted – The Future of AI, Data & Precision Medicine. The event, hosted at the Union League Club in New York City, will provide a global platform for the hospital to highlight how locally developed CAR-T manufacturing capabilities are reshaping access, reducing costs, and advancing international standards of care.

By building local biomanufacturing capabilities, KFSHRC underscores its mission to advance Vision 2030 and the National Biotechnology Strategy, ensuring patients in Saudi Arabia and beyond benefit early from next-generation therapies while reinforcing its role as a global reference center for healthcare innovation.

It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6c485d4-ac4c-4df3-9b9b-5a0cc7979618

KFSHRC Reinforces Global Leadership as Early Adopter of Advanced cell and Gene Therapies Read More »

KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients

KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients

KFSHRC recorded a 47% surge in international patients in 2024, reinforcing its position as one of the fastest-growing destinations for medical tourism.
KFSHRC recorded a 47% surge in international patients in 2024, reinforcing its position as one of the fastest-growing destinations for medical tourism.

RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC), ranked 15th globally by Brand Finance, recorded a 47% surge in international patients in 2024, strengthening its position as a fast-growing destination for medical tourism under Saudi Arabia’s Vision 2030 to diversify the economy and expand high-value healthcare services.

The sharp rise significantly outpaces global benchmarks, where leading institutions typically record annual international patient growth in the low single digits. This momentum is underpinned by KFSHRC’s more than 50 years of expertise in tertiary and highly specialized healthcare, making it a trusted center for patients seeking advanced and complex treatment.

KFSHRC’s international appeal is anchored in its record of world-first achievements in complex specialties, including robotic liver and heart transplants, as well as leadership in advanced gene and cell therapies. These milestones underscore both the hospital’s role as a global center of excellence and Saudi Arabia’s ambition to emerge as a hub for advanced medical care.

KFSHRC’s momentum is further supported by Saudi Arabia’s geographic location, which places the Kingdom within a six-to-eight-hour flight from Europe, Africa, and much of Asia. In the post-COVID era, this accessibility has become a decisive factor, as patients increasingly seek shorter travel distances for complex medical treatments. This advantage enhances KFSHRC’s ability to sustain its rapid growth in international patient admissions and strengthens its position as one of the fastest-growing destinations for advanced care.

The growth of international admissions at KFSHRC reflects not only rising global confidence in Saudi medical expertise but also contributes directly to the Kingdom’s economic diversification goals, supporting the development of a sustainable and high-value healthcare sector under Vision 2030.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally among the world’s top 250 Academic Medical Centers for the second consecutive year. It has also been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. In addition, Newsweek magazine included KFSHRC in the World’s Best 250 Hospitals and the World’s Best Smart Hospitals 2025 lists.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/945b1b8f-80b9-4a76-af87-9893590b1a19

KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients Read More »

KFSHRC Sets Global Benchmark in Robotic Surgery, Expanding World-First Innovations

KFSHRC Sets Global Benchmark in Robotic Surgery, Expanding World-First Innovations

KFSHRC is now moving to expand the use of robotic surgery across all operating rooms, aiming to make it the first choice for complex procedures in the future. This ambition is already visible: robotic kidney transplants at KFSHRC Riyadh increased by 75.2% in 2024, underscoring both the rising patient demand and the hospital’s growing capacity to deliver advanced robotic care.
KFSHRC is now moving to expand the use of robotic surgery across all operating rooms, aiming to make it the first choice for complex procedures in the future. This ambition is already visible: robotic kidney transplants at KFSHRC Riyadh increased by 75.2% in 2024, underscoring both the rising patient demand and the hospital’s growing capacity to deliver advanced robotic care.

RIYADH, Saudi Arabia, Aug. 29, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) is redefining global standards in robotic surgery, building on unprecedented world-firsts including the first fully robotic liver transplant led by Prof. Dieter Broering and the first fully robotic heart transplant performed by Prof. Feras Khaliel to advance a future where robotics becomes the preferred approach for complex procedures.

These pioneering operations illustrate how robotics is reshaping the most complex surgical interventions into safer, less invasive procedures that enable faster recovery and better outcomes. Patients who once faced weeks of hospitalization after major transplants are now returning home in just days, with reduced complications and improved quality of life.

The hospital’s expertise also extends beyond global milestones, with regional firsts such as the Middle East’s first robotic abdominal lymph node dissection and the first robot-assisted stereo-electroencephalography (SEEG) intracranial electrode implantation to localize seizure foci for epilepsy surgery. Together, these achievements reflect KFSHRC’s commitment to integrating cutting-edge technologies that enhance surgical precision, reduce patient risk, and accelerate recovery times.

KFSHRC is now moving to expand the use of robotic surgery across all operating rooms, aiming to make it the first choice for complex procedures in the future. This ambition is already visible: robotic kidney transplants at KFSHRC Riyadh increased by 75.2% in 2024, underscoring both the rising patient demand and the hospital’s growing capacity to deliver advanced robotic care.

As an early adopter in embracing healthcare innovations, KFSHRC is not only delivering transformative care within the Kingdom but also contributing knowledge to the international medical community. By investing in robotics, training, and multidisciplinary collaboration, the institution is building capacity for the next generation of surgeons and reinforcing its alignment with Saudi Arabia’s Vision 2030.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world’s best 250 hospitals and included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f674f09d-86ea-4d8e-988c-6e4a81c012d2

KFSHRC Sets Global Benchmark in Robotic Surgery, Expanding World-First Innovations Read More »

Dimora PHMB Cleanser Brings Clinical-Grade Wound Care Into Everyday Homes

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) — Chronic wounds remain one of the toughest challenges in modern healthcare. Dimora Medical, a company dedicated to simplifying chronic disease care for aging populations, today launches Dimora PHMB Skin and Wound Cleanser to help close that gap in chronic wound care. Research shows that more than 78% of chronic wounds are complicated by biofilms, which are protective layers of bacteria that slow healing and increase infection risk. The PHMB Skin and Wound Cleanser is designed to break down stubborn biofilms and kill 99.99% of bacteria within minutes. Simple to use and backed by strong clinical evidence, it helps caregivers protect loved ones more effectively while easing the burden of home wound care.

Breaking Down Biofilms for Faster Healing

The Dimora PHMB Cleanser can break down biofilms for faster healing

One of the standout features of the Dimora PHMB Skin and Wound Cleanser is its ability to tackle biofilms, a hidden barrier that makes chronic wounds so hard to treat. Biofilms are slimy layers formed by bacteria on the wound surface. They protect microbes from the body’s defenses and from treatments, often delaying healing and raising the risk of infection.

The cleanser’s main ingredient, Polyhexamethylene Biguanide (PHMB), has been shown to break down these biofilms quickly and effectively. In tests, PHMB removed 99.49% of biofilm within three minutes and reached 99.99% after seven minutes. Once the biofilm barrier is cleared, antimicrobial dressings and the body’s natural healing process can work as intended. Compared with hypochlorous or saline-based solutions, PHMB has consistently demonstrated stronger activity against biofilms of common wound pathogens like Staphylococcus aureus and Pseudomonas aeruginosa.

For caregivers at home, this means fewer complications, less risk of infection, and a more reliable path to wound healing. It’s an advanced solution that brings clinical-level effectiveness into everyday care.

Rapid Antimicrobial Power for Safer Home Care

The Dimora PHMB Cleanser can cleanse the wound surface

Beyond clearing biofilms, the Dimora PHMB Skin and Wound Cleanser works as an antiseptic skin cleanser, delivering fast and powerful antimicrobial action. For infected wounds, it kills 99.99% of bacteria in just two minutes. For non-infected wounds, that same level of protection is reached in as little as one minute. That kind of speed matters in home care, where infection risk is high and every delay can slow recovery.

In practical terms, this means a caregiver can clean and protect a wound quickly without multiple steps or long waiting times. Families managing diabetic foot ulcers, post-surgical incisions, or even everyday cuts in older adults know that speed makes a difference. Each application reduces the chance of infection, lowers stress for the caregiver, and keeps the patient more comfortable at home. By minimizing complications, the cleanser also helps families avoid repeat clinic visits and gives them greater confidence in daily wound management.

Long-Lasting Protection Families Can Count On

Dimora PHMB Cleanser

Consistency matters in wound care, especially for families managing chronic conditions day after day. The Dimora PHMB Skin and Wound Cleanser isn’t just effective the first time you use it—it maintains its antimicrobial strength over time. In testing under USP <51>, an internationally recognized standard for antimicrobial effectiveness, the cleanser exceeded expectations. Even after being opened for 28 days, it still delivered a 99.99% reduction in bacteria, ensuring safety and stability with every use. For caregivers at home, this reliability goes beyond a technical detail. It means fewer worries about whether a bottle has lost its strength or needs to be replaced too quickly. By contrast, hypochlorous-based solutions are less stable and less effective against wound pathogens over time. PHMB gives families peace of mind and consistent performance. With Dimora, caregivers can spend less energy tracking expiration dates and more time focusing on what truly matters—supporting their loved one’s healing.

Making Home Care Easy, Reliable, and Safe

The Dimora PHMB Cleanser makes home care easy, reliable, and safe

Dimora’s vision is clear: make home care easy and become the trusted wound care expert for families. The PHMB Skin and Wound Cleanser reflects that mission by bringing clinical strength into everyday use. Acting as a wound wash, antiseptic skin cleanser, and reliable antibacterial wash, it supports chronic wound care at home. From diabetic foot ulcers to surgical sites, its proven biofilm removal gives patients a better path to healing and provides caregivers with real peace of mind.

For families, that means fewer complications, less stress, and safer home care with every use. The Dimora PHMB Skin and Wound Cleanser is available now for $15.99 on Amazon

About Dimora

Dimora develops advanced solutions for chronic disease and wound care. With 34 years of experience in medical supplies, Dimora is dedicated to making home care easy, safe, and less stressful for families.

Press Contact:
Contact Person: Alisa Yen
Email:support@dimoramedical.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/691ce3e6-9d2f-4b49-88a1-078a31cc6512

https://www.globenewswire.com/NewsRoom/AttachmentNg/05cd46b1-df6b-4f45-8469-b8546751325e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c2316217-dc99-40f6-8b1e-0788ee2a520e

https://www.globenewswire.com/NewsRoom/AttachmentNg/06def58c-5435-41cb-a130-2c007cae88c8

Dimora PHMB Cleanser Brings Clinical-Grade Wound Care Into Everyday Homes Read More »

Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy

KFSHRC Achieves a Breakthrough in Treating Epilepsy Through Stereo-EEG

KFSHRC Achieves a Breakthrough in Treating Epilepsy Through Stereo-EEG

Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy
Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy

RIYADH, Saudi Arabia, Aug. 25, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has reinforced its Epilepsy Centre’s position as one of the world’s most active in Stereo-Electroencephalography (Stereo-EEG) procedures, with a rate of 1 to 2 cases per week, making it the largest epilepsy surgery centre in the Middle East and advancing its role in providing cutting-edge solutions for drug-resistant epilepsy.

Since 1993, the Epilepsy Centre has treated more than 4,000 patients and successfully performed over 2,000 epilepsy surgeries for patients unresponsive to medication, before launching the Stereo-EEG program in the last two years as a minimally invasive and advanced diagnostic tool that improves seizure localization and reduces complications.

The technique represents a transformative advancement in the treatment of drug-resistant epilepsy, enabling precise identification of seizure foci and supporting tailored treatment plans such as targeted resection or neurostimulation implants, which restore independence and improve quality of life for many patients.

The procedure involves placing ultra-thin electrodes through millimeter-sized openings in the skull to precisely localize seizure foci, thereby minimizing risks associated with traditional open surgery and enabling treatment strategies that have resulted in the majority of patients achieving full seizure control and regaining independence. This innovation also reduces long-term healthcare costs by lowering reliance on expensive anti-seizure medications with significant side effects, while helping patients return to work faster and reducing productivity losses.

According to the World Health Organization, epilepsy affects around 50 million people worldwide, with 30% of patients resistant to medication, a condition that severely impacts their ability to work, drive, and maintain daily activities, making surgery the only viable option to restore quality of life.

This milestone reflects KFSHRC’s vision of advancing neurosciences by leveraging state-of-the-art diagnostic and surgical technologies in the treatment of drug-resistant epilepsy, reinforcing its role as a leader in medical innovation and supporting the Kingdom’s global standing in specialized healthcare.

It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a17750d5-a761-4d68-8988-ace9e24092f1

Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy Read More »

KFSHRC Saves Saudi 7-Year-Old Through Cross-Border Heart Transplant with UAE Donor Organ

KFSHRC Saves Saudi 7-Year-Old Through Cross-Border Heart Transplant with UAE Donor Organ

King Faisal Specialist Hospital and Research Centre in Riyadh has successfully performed a life-saving heart transplant on a 7-year-old Saudi child using an organ donated by a brain-dead donor in Abu Dhabi, United Arab Emirates.
King Faisal Specialist Hospital and Research Centre in Riyadh has successfully performed a life-saving heart transplant on a 7-year-old Saudi child using an organ donated by a brain-dead donor in Abu Dhabi, United Arab Emirates.

RIYADH, Saudi Arabia, Aug. 21, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed a life-saving heart transplant on a 7-year-old Saudi child using an organ donated by a brain-dead donor in Abu Dhabi, United Arab Emirates.

The complex procedure was made possible through seamless cross-border cooperation between the Saudi Center for Organ Transplantation and the UAE’s National Program for Donation and Transplantation of Human Organs and Tissue (HAYAT), with full consent from the donor’s family and all regulatory approvals in place.

This cooperation involved precise medical and logistical coordination, starting with the organ extraction, followed by air transportation to Riyadh, and concluding with the preparation of operating theaters in record time. The transplantation was performed within a critically time-sensitive window, ultimately saving the life of a child who had no other treatment options available.

The medical team at KFSHRC performed the transplantation on the child, who was suffering from advanced heart failure due to a complex congenital heart defect. After exhausting all available treatment options—including medications, respiratory support, and pacemaker implantation—without any significant improvement, the child was placed on the urgent transplant list.

Time is a critical factor in heart transplant operations. According to medical standards, the period between removing the heart from the donor and transplanting it into the patient must not exceed five hours to ensure transplant success. This time constraint creates significant logistical challenges in addition to the complex medical procedures, particularly when the brain-dead donor is located in another region within the Kingdom or overseas. In such circumstances, every minute of delay becomes crucial to the operation’s success.

The KFSHRC Heart Centre is recognized as one of the world’s leading cardiac centers, having achieved exceptional milestones including the world’s first fully robotic heart transplant and robotic artificial heart pump implantation without chest incision. These unprecedented medical breakthroughs demonstrate the Kingdom’s leadership in complex cardiac surgery.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. It was included in the world’s best 250 hospitals and in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aaf4d900-7f18-4871-9809-29e19875c14a

KFSHRC Saves Saudi 7-Year-Old Through Cross-Border Heart Transplant with UAE Donor Organ Read More »

King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024

King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024

KFSHRC delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become central to the hospital’s care model, helping ease pressure on outpatient clinics while giving patients across the Kingdom faster and more convenient access to specialized care.
KFSHRC delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become central to the hospital’s care model, helping ease pressure on outpatient clinics while giving patients across the Kingdom faster and more convenient access to specialized care.

RIYADH, Saudi Arabia, Aug. 20, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become central to the hospital’s care model, helping ease pressure on outpatient clinics while giving patients across the Kingdom faster and more convenient access to specialized care.

Launched in 2021, the virtual consultation service was introduced to reduce travel burdens for patients in remote areas. For many, particularly the elderly and those living with chronic conditions, it has eliminated the need for repeated hospital visits, improved quality of life, and removed financial and logistical barriers by connecting them directly with specialists from home.

With an average of more than 800 virtual visits each day, the service has eased pressure on outpatient facilities, boosted operational efficiency, and allowed KFSHRC to optimize resources while maintaining the highest standards of care for both in-person and remote patients.

Building on this momentum, KFSHRC expanded its digital health portfolio in 2024 with the launch of a virtual pharmacy consultation service through its mobile application. Patients can now book appointments under the Virtual Care option to connect with pharmacists for guidance on medication alternatives, dosage adjustments, and treatment management—all without visiting the hospital.

These programs demonstrate how KFSHRC is making healthcare more accessible and efficient, while keeping patients at the center of care. By combining digital solutions with clinical expertise, the hospital is reducing unnecessary travel, shortening waiting times, and ensuring patients have timely access to specialists wherever they live.

These initiatives also support Saudi Arabia’s broader healthcare transformation goals under Vision 2030, ensuring that high-quality care reaches more people while resources are used more effectively across the health system.

KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world’s top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. It was included in the world’s best 250 hospitals and in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.

For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ea4636ac-4872-4b9b-9855-a51dc9f45d34

King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024 Read More »

SUCCESS FOR VITAHEALTH & TROPICANA:OFFLINE 16 PICKLEBALL CHALLENGE EVENT SCORES 1,320 PARTICIPANTS IN 2025

• The OFFLINE 16 ESG event by VitaHealth and Tropicana has been gaining popularity and traction since  its first kick-off in 2024. Entering its second year, OFFLINE 16 recorded a total of 1,320 participants so  far.  • Its recent flagship event held at Tropicana Golf & Country Resort was a great success, recording 310  participants,

SUCCESS FOR VITAHEALTH & TROPICANA:OFFLINE 16 PICKLEBALL CHALLENGE EVENT SCORES 1,320 PARTICIPANTS IN 2025 Read More »

To “Eat” or to “Escape”? NTHU Uncovers Olfactory Code of Fruit Fly Brain

HSINCHU, Taiwan, Aug. 15, 2025 (GLOBE NEWSWIRE) — The Director of the Brain Research Center at National Tsing Hua University (NTHU) in Taiwan, Ann-Shyn Chiang (江安世), Professor of the Institute for Systems Neuroscience, Chung-Chuan Lo (羅中泉), and Distinguished Chair Professor of the Department of Physics, Ting-Kuo Lee (李定國), led a cross-disciplinary team that has uncovered how fruit flies (Drosophila melanogaster) rapidly decide to either “eat” or “escape.” The study found that their brains transmit olfactory signals through a hybrid neural network, using so-called generalist neurons to process common odors such as pheromones and floral scents, and specialist neurons to handle the most crucial food-related odors.

Scientists once believed that neural connectivity in the fruit fly’s brain was random. However, Ann-Shyn Chiang discovered that these connections not only include random components but also feature dedicated “specialist lines” — precise and efficient pathways responsible for processing more critical information. The findings shed new light on the neural computing mechanisms of insect brains and may pave the way for future applications that bridge brain science and artificial intelligence. The research was recently published in Science Advances, a leading international journal.

The mushroom body, located at the center of the fruit fly’s brain, is the crucial hub for processing sensory information and supporting learning and memory. For the past two decades, scientists have held different views about the neural connectivity of the mushroom body. Nobel laureate Richard Axel (2004, Physiology or Medicine) analyzed roughly 10% of the relevant neurons and concluded that the neural connections were random. On the other hand, Ann-Shyn Chiang has argued that there may be specific patterns of connectivity within the fruit fly’s brain.

Chiang, a renowned neuroscientist and Academician of Academia Sinica, led a research team at NTHU that used neural connectome analysis, in vivo imaging technology, and computer simulation to study the hemibrain dataset. The team discovered that the connectivity between olfactory nerves and central neurons is neither entirely random nor completely stereotypic, but rather follows a hybrid pattern that combines both random and stereotypic features. Specific neural clusters exhibit clear preferences for connection partners, encoding different odors through both dispersed and convergent patterns, balancing the sensitivity and diversity of olfactory recognition.

The mushroom body in the fruit fly’s brain works like a miniature central processing unit (CPU), integrating various types of sensory input to assist the fruit fly in making decisions in complex environments, such as avoiding risks, finding food, or locating a mate.

The research team at NTHU found that the olfactory neurons of the fruit fly are divided into two functional types: “specialists” and “generalists.” Generalist neurons can respond to a wide range of odors — including food, pheromones, flowers, and trees — and diffuse signals to multiple neural circuits simultaneously, much like a radio transmission. In contrast, specialist neurons manage only key odors, such as those associated with food like fruit. They function more like a dedicated phone line, centralizing key information directly to designated neurons.

Professor Chung-Chuan Lo, from the Institute for Systems Neuroscience, further explained that the hybrid neural connections in fruit flies resemble a strong password — one that blends randomness and order. “Just like the way an ideal password combines familiar words with random characters, such as adding numbers or symbols to a name, the structure may seem illogical at first, but it is both easy to remember and difficult to decode,” Lo said.

Ann-Shyn Chiang noted that the discovery of hybrid neural connections in fruit flies, which combine both random and orderly features, sheds light on how the brain distributes and integrates information. It is also expected to offer new insights into the treatment of neurodegenerative diseases such as dementia and Parkinson’s disease, as well as provide inspiration for the design and application of AI neural networks.

The first authors of the paper are Li-Shan Cheng (鄭力珊), a master’s student from the Department of Physics, and Ching-Che Charng (強敬哲), a doctoral student in the Institute for Systems Neuroscience. The corresponding authors are Distinguished Chair Professor Ann-Shyn Chiang, Professor Chung-Chuan Lo, and Distinguished Chair Professor of the Department of Physics Ting-Kuo Lee. The NTHU research team also includes Kuan-Lin Feng (馮冠霖), a postdoctoral researcher at the Brain Research Center, and Ruei-Huang Chen (陳瑞煌), a doctoral student at the Department of Neuroscience. Feng was responsible for studying the biology and behavior of fruit flies, while Chen used functional imaging experiments to observe how olfactory information is transmitted in neural networks.

Ann-Shyn Chiang pointed out that Li-Shan Cheng and Ching-Che Charng led the team’s core theoretical analysis, while Ruei-Huang Chen and Kuan-Lin Feng were the scientists responsible for experimental testing. “The key to unraveling the neural connectivity of fruit flies is to combine cross-disciplinary collaboration in physics, neuroscience, and behavioral research,” Chiang said.

The NTHU Laboratory of Brain and Intelligence initiated the research on fruit fly neural connections in collaboration with Taiwan’s China Medical University (CMU), the National Health Research Institutes, Academia Sinica, and the Kavli Institute for Brain and Mind Research at the University of California, San Diego. The project received support from Taiwan’s Ministry of Education, the National Science and Technology Council (NSTC), and the Peng Education and Welfare Foundation.

Contact:
 Holly Hsueh
 NTHU
 (886)3-5162006
 hoyu@mx.nthu.edu.tw

Fruit Fly Brain

The Director of the NTHU Brain Research Center, Ann-Shyn Chiang (江安世, front-right), and Professor Chung-Chuan Lo (羅中泉, front-left) of the Institute for Systems Neuroscience led a cross-disciplinary team to crack the code of the fruit fly’s brain. The team included Ruei-Huang Chen (陳瑞煌, from back-left), a doctoral student at NTHU’s Institute of Systems Neuroscience; Li-Shan Cheng (鄭力珊), a master’s student in NTHU’s Department of Physics; Ching-Che Charng (強敬哲), a doctoral student from the Institute of Systems Neuroscience; and Guan-Lin Feng (馮冠霖), a postdoctoral researcher at the Brain Research Center. (Photo: National Tsing Hua University)

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/738adc57-2d8f-451f-8d67-ae0ad78bb063

To “Eat” or to “Escape”? NTHU Uncovers Olfactory Code of Fruit Fly Brain Read More »

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30%

New anti-colic system delivers clinically tested relief for newborn digestive discomfort BEIJING, Aug. 6, 2025 /PRNewswire/ — Thyseed, an established name in global infant care, has announced the launch of its newborn baby bottle featuring proprietary bottom vent technology for global markets. Clinical trials confirm that this design reduces colic and spit-up by more than 30% among infants

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30% Read More »